alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 31.1




KALEX CORP.


Certification Pursuant to


Section 302 of the Sarbanes-Oxley Act of 2002




I, Norman King, Chairman of the Board and CEO, certify that:




1. I have reviewed this annual report on Form 10-K of Kalex Corporation;




2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;




3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;




4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and I have:




(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;




(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;




(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and




(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that was materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and




5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors:




(a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and




(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.




Date: March 16, 2011





/s/ Norman KingNorman KingChairman of the Board of Directors and CEO
17.108 Congressional notification.       (a) 						             Except for DoD, NASA, and the Coast Guard, a multi-year contract which includes a cancellation ceiling in excess of  							$15 million 						 may not be awarded until the head of the agency gives written notification of the proposed contract and of the proposed cancellation ceiling for that contract to the committees on appropriations of the House of Representatives and Senate and the appropriate oversight committees of the House and Senate for the agency in question. Information on such committees may not be readily available to contracting officers. Accordingly, agencies should provide such information through its internal regulations. The contract may not be awarded until the thirty-firstday after the date of notification.                                          (b) 						             For DoD, NASA, and the Coast Guard, a multi-year contract which includes a cancellation ceiling in excess of  							$150 million 						 may not be awarded until the head of the agency gives written notification of the proposed contract and of the proposed cancellation ceiling for that contract to the committees on armed services and appropriations of the House of Representatives and Senate. The contract may not be awarded until the thirty-firstday after the date of notification.    **Parent topic:** Subpart 17.1 - Multi-year Contracting
# L_2023178DE.01001001.xml

| 13.7.2023 | DE | Amtsblatt der Europäischen Union | L 178/10 |
| --- | --- | --- | --- |

13.7.2023

DE

Amtsblatt der Europäischen Union

L 178/10

---

Berichtigung der Durchführungsverordnung (EU) 2021/1248 der Kommission vom 29. Juli 2021 über Maßnahmen zur guten Vertriebspraxis für Tierarzneimittel gemäß der Verordnung (EU) 2019/6 des Europäischen Parlaments und des Rates

(
  Amtsblatt der Europäischen Union L 272 vom 30. Juli 2021
  )

Seite 49, Artikel 2 Buchstabe h:

Anstatt:

| „h) | ‚Dokumentation‘ schriftlich niedergelegte Verfahren, Anweisungen, Verträge, Berichte und Daten auf Papier oder in elektronischer Form;“ |
| --- | --- |

„h)

‚Dokumentation‘ schriftlich niedergelegte Verfahren, Anweisungen, Verträge, Berichte und Daten auf Papier oder in elektronischer Form;“

muss es heißen:

| „h) | ‚Dokumentation‘ schriftlich niedergelegte Verfahren, Anweisungen, Verträge, Aufzeichnungen und Daten auf Papier oder in elektronischer Form;“. |
| --- | --- |

„h)

‚Dokumentation‘ schriftlich niedergelegte Verfahren, Anweisungen, Verträge, Aufzeichnungen und Daten auf Papier oder in elektronischer Form;“.

Seite 54, Artikel 12 Absatz 7 Satz 1:

Anstatt:

„Alle abgelaufenen, zurückgerufenen und zurückgewiesenen Tierarzneimittel werden unverzüglich physisch und, sofern ein elektronisches System vorhanden ist, elektronisch abgesondert und in einem speziell dafür eingerichteten Bereich abseits von den übrigen Tierarzneimittel gelagert.“

muss es heißen:

„Alle abgelaufenen, zurückgerufenen und zurückgewiesenen Tierarzneimittel werden unverzüglich physisch abgesondert und in einem speziell dafür eingerichteten Bereich abseits von den übrigen Tierarzneimittel gelagert.“

Seite 54, Artikel 12 Absatz 12 Satz 2:

Anstatt:

„Es existieren Reinigungsprogramme, -anweisungen und -berichte.“

muss es heißen:

„Es existieren Reinigungsprogramme, -anweisungen und -aufzeichnungen.“

Seite 56, Artikel 17 Absatz 2 Sätze 2 und 3:

Anstatt:

„Sie wird nicht handschriftlich verfasst, es sei denn, handschriftliche Einträge sind aus pra ktischen Gründen gerechtfertigt. In diesem Fall wird ausreichend Platz für entsprechende handschriftliche Einträge gelassen.“

muss es heißen:

„Sie wird nicht handschriftlich verfasst, es sei denn, handschriftliche Aufzeichnungen sind aus praktischen Gründen gerechtfertigt. In diesem Fall wird ausreichend Platz für entsprechende handschriftliche Aufzeichnungen gelassen.“

---
[Federal Register Volume 75, Number 227 (Friday, November 26, 2010)]
[Notices]
[Pages 72832-72833]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-29752]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C.,

[[Page 72833]]

as amended. The grant applications and the discussions could disclose 
confidential trade secrets or commercial property such as patentable 
material, and personal information concerning individuals associated 
with the grant applications, the disclosure of which would constitute a 
clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel, Member Conflict: AIDS and Related Research.
    Date: December 16-17, 2010.
    Time: 9 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892. (Virtual Meeting.)
    Contact Person: Robert Freund, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 3200, MSC 7848, Bethesda, MD 20892. 301-435-
1050. <a href="/cdn-cgi/l/email-protection#284e5a4d5d464c5a684b5b5a06464140064f475e"><span class="__cf_email__" data-cfemail="4f293d2a3a212b3d0f2c3c3d6121262761282039">[email protected]</span></a>.

    Name of Committee: Bioengineering Sciences & Technologies 
Integrated Review Group, Instrumentation and Systems Development 
Study Section.
    Date: January 27-28, 2011.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: The Westin St. Francis, 335 Powell Street, San Francisco, 
CA 94102.
    Contact Person: Raymond Jacobson, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, MSC 7849, Bethesda, MD 20892. 301-435-
0483. <a href="/cdn-cgi/l/email-protection#7913181a161b0a16170b11391a0a0b57171011571e160f"><span class="__cf_email__" data-cfemail="2a404b49454859454458426a49595804444342044d455c">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: November 19, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-29752 Filed 11-24-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
#### Nunzio S. Maisto, Respondent, v Marguerite H. Maisto, Appellant.

In an action for partition of real property formerly owned by the parties as tenants by the entirety, the defendant appeals from an order of the Supreme Court, Nassau County dated November 20, 1979, which (1) denied her motion for summary judgment upon her counterclaim, and (2) granted, *sua sponte,*partial summary judgment to the plaintiff dismissing the counterclaim without prejudice to an application by the defendant for a judgment pursuant to section 244 of the Domestic Relations Law. Order modified, on the law, by deleting the provision granting partial summary judgment to the plaintiff dismissing the counterclaim. As so modified, order affirmed, without costs or disbursements. Under the circumstances of this case, Special Term erred in dismissing the defendant’s counterclaim for arrears due under a judgment of divorce. A formal application pursuant to section 244 of the Domestic Relations Law may be dispensed with in appropriate circumstances. (See *McDonald v McDonald,*30 AD2d 866.) In the case at bar, the defendant should have been permitted to interpose a counterclaim for arrears in an action brought by her former husband for partition of the marital home. Moreover, we are of the view that there are issues of fact which preclude summary judgment herein. (See *Salvati v Salvati,*37 AD2d 858.) Mangano, J. P., Gulotta, Cohalan and Margett, JJ., concur.
----

Exhibit 32.1

**CERTIFICATION PURSUANT TO**** 18 U.S.C. SECTION 1350,**** AS ADOPTED PURSUANT TO**** SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

             In connection with the Quarterly Report of Amalgamated Pictures Corp. (the  "Company") on Form 10-QSB for the quarter ending September 30, 2006  as filed with the Securities and Exchange Commission on the date hereof  (the "Report"), I, Avery Pack,  President, certify, pursuant to 18 U.S.C. Section  1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of  2002, that:

             (1) The Report fully complies with the requirements of Section 13(a) or  15(d) of the Securities Exchange Act of 1934; and

             (2) The information contained in the Report fairly presents, in all  material respects, the financial condition and result of operations of the  Company.

Date: November 13, 2006

| /s/ Avery Pack                                                                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                      |
| Avery Pack,      President and Chief Executive      Officer      (Principal Executive Officer)      and      Acting Chief Financial Officer      (Principal Financial Officer      and      Principal Accounting Officer) |
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsThe determination of the orbit of the Japanese satellite Ajisai and the GEM-T1 and GEM-T2 gravity field modelsThe Japanese Experimental Geodetic Satellite Ajisai was launched on August 12, 1986. In response to the TOPEX-POSEIDON mission requirements, the GSFC Space Geodesy Branch and its associates are producing improved models of the Earth's gravitational field. With the launch of Ajisai, precise laser data is now available which can be used to test many current gravity models. The testing of the various gravity field models show improvements of more than 70 percent in the orbital fits when using GEM-T1 and GEM-T2 relative to results obtained with the earlier GEM-10B model. The GEM-T2 orbital fits are at the 13-cm level (RMS). The results of the tests with the various versions of the GEM-T1 model indicate that the addition of satellite altimetry and surface gravity anomalies as additional data types should improve future gravity field models.Document ID19900016127Acquisition SourceLegacy CDMSDocument TypeTechnical Memorandum (TM)AuthorsSanchez, Braulio V.*(NASA Goddard Space Flight Center Greenbelt, MD, United States)*Date AcquiredSeptember 6, 2013Publication DateJune 1, 1990Subject CategoryGeophysicsReport/Patent NumberNASA-TM-100763REPT-90E02466NAS 1.15:100763Accession Number90N25443Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType19900016127.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
**EVEREST HICKORY GLEN, LP**

**AMENDED AND RESTATED**

**AGREEMENT OF LIMITED PARTNERSHIP**

 

This Amended and Restated Agreement of Limited Partnership of Everest Hickory Glen, LP (the “Partnership”), effective as of December 6, 2006, is entered into by and among the Partners set forth below, pursuant to the Kansas Revised Uniform Limited Partnership Act (the “Act”) on the following terms and conditions.

 

| **1.** | **Organization.** |
|--------|-------------------|

 

1.1       Formation. On or about March 26, 1999, the Partnership was organized as a Kansas limited partnership under the name “Oak Terrace Joint Venture, L.P.” by executing and delivering a Certificate of Limited Partnership to the Secretary of State in accordance with and pursuant to the Act, which was filed on March 26, 1999 (the “Original Certificate”). The original Agreement of Limited Partnership of the Partnership was made and entered into as of March 31, 1999. On or about December 6, 2006, an Amended and Restated Certificate of Limited Partnership was filed with the Secretary of State in accordance with and pursuant to Section 56-la160 of the Act.

 

1.2       Name and Place of Business. The name of the Partnership shall be Everest Hickory Glen, LP (the “Partnership”), and its principal place of business shall be 199 S. Los Robles Avenue, Suite 200, Pasadena, California 91101. The General Partner may change the name and or the principal place of business of the Partnership as the General Partner may reasonably determine to be necessary or desirable.

 

1.3       Business and Purpose: The business of the Company shall be (a) to accomplish any lawful business whatsoever, conducive to or expedient for the protection or benefit of the Company and its assets and related, directly or indirectly, to the acquisition, management or disposition of the Property (as defined below), (b) the exercise of all other powers necessary to or reasonably connected with the Partnership’s business which may be legally exercised by a limited partnership under the Act, and (c) to engage in all activities necessary, customary, convenient, or incidental to any of the foregoing.

 

1.4       Term. The Partnership commenced on the filing of the Original Certificate with the Secretary of State, and shall continue for the period ending December 31, 2040 or for such longer period as may be agreed upon by the Partners and permitted by the Act, unless earlier terminated in accordance with the provisions of this Agreement or the Act.

 

1.5       Registered Agent. The Partnership’s registered agent shall be as provided in the Amended and Restated Certificate of Limited Partnership. The registered agent may be changed from time to time by filing the name of the new registered agent pursuant to the Act.

 

----
EXHIBIT 

31.2 

CERTIFICATIONS 

I, George Lefevre, certify that: 

 

1. I have reviewed this quarterlyreport on Form 10-QSB of EntreMetrix Corporation (the "Company") for thequarterly period ending September 30, 2004.

 

2. Based on my knowledge, thisquarterly report does not contain any untrue statement of a material fact oromit to state a material fact necessary to make the statements made, in light ofcircumstances under which such statements were made, not misleading with respectto the period covered by the quarterly report; and 

 

3. Based on my knowledge, thefinancial statements, and other financial information included in this quarterlyreport, fairly present in all material respects the financial condition, resultsof operations and cash flows of the Company as of, and for, the periodspresented in the quarterly report. 

 

4. The registrant's other certifyingofficer and I are responsible for establishing and maintaining disclosurecontrols and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) forthe Company and have: 

 

a) designed such disclosure		controls and procedures, or caused such disclosure controls and		procedures to be designed under our supervision, to ensure that material		information relating to the Company, including its consolidated		subsidiaries, is made known to us by others within those entities,		particularly during the period in which the quarterly report is being		prepared; 

b) evaluated the		effectiveness of the Company's disclosure controls and procedures and		presented in the quarterly report our conclusions about the		effectiveness of the disclosure controls and procedures, as of the end		of the period covered by the quarterly report based on such evaluation;		and 

 

c) disclosed in the quarterly		report any change in the Company's internal control over financial		reporting that occurred during the Company's most recent fiscal quarter		that has materially affected, or is reasonably likely to materially		affect, the Company's internal control over financial reporting; 

 

5. The registrant's other certifyingofficer and I have disclosed, based on our most recent evaluation of internalcontrol over financial reporting, to the Company's auditors and the auditcommittee of Company's board of directors (or persons performing the equivalentfunctions); 

 

a) all significant		deficiencies in the design or operation of internal controls which could		adversely affect the Company's ability to record, process, summarize and		report financial data and have identified for the Company's auditors any		material weaknesses in internal controls; and 

 

b) any fraud, whether or not		material, that involves management or other employees who have a		significant role in the Company's internal controls over financial		reporting. 

 

 

| Dated: November 15, 2004   | By: /s/George Lefevre                  |
|--------------------------------------|----------------------------------------|
|                            | George Lefevre, Chief FinancialOfficer |
CE A SAR MONTOYA SOLTERO,

Appellant,

v.

THE STATE OF TEXAS,

Appellee. §

§

§

§

§

§ No. 08

- 19

- 00146

- CR

Appeal from the

109th District Court

of Winkler County, Texas

(TC# DC18

- 5722)

J U D G M E N T

The Court has considered this cause on the record and concludes there was no reversible

error in the judgment. We therefore affirm the judgment of the court below. This decision shall be

certified below for observance.

IT IS SO ORDERED THIS 9 TH OF DECEMBER, 2020.

YVONNE T. RODRIGUEZ, Justice

Before Alley, C.J., Rodriguez, and Palafox, JJ.
<PAGE>

                                                                    EXHIBIT 32.2

                     CERTIFICATE OF CHIEF FINANCIAL OFFICER
                 PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      This Certificate is being delivered pursuant to the requirements of
Section 1350 of Chapter 63 (Mail Fraud) of Title 18 (Crimes and Criminal
Procedures) of the United States Code and shall not be relied on by any person
for any other purpose.

      The undersigned, who is the Chief Financial Officer of Orion HealthCorp,
Inc. (the "small business issuer"), hereby certifies as follows:

      The Quarterly Report on Form 10-QSB of the small business issuer (the
"Report"), which accompanies this Certificate, fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934,
and all information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the small
business issuer.

Dated this 13th day of May, 2005.

/s/ Stephen H. Murdock
---------------------------------------------
Stephen H. Murdock, Chief Financial Officer
(Principal Accounting Officer)

A signed original of this written statement required by Section 906 of the
Sarbanes-Oxley Act of 2002 has been provided to the small business issuer and
will be retained by the small business issuer and furnished to the Securities
and Exchange Commission or its staff upon request.